AlphaCentric Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

AlphaCentric Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$596K	Buy	+7,987	New	+$588K	0.53%	58
2024 Q4	–	Sell	-11,478	Closed	-$287K	–	253
2024 Q3	$287K	Buy	+11,478	New	+$280K	0.21%	111
2023 Q4	–	Sell	-110,000	Closed	-$1.91M	–	266
2023 Q3	$1.91M	Hold	110,000	–	–	1.08%	30
2023 Q2	$1.55M	Buy	110,000 +27,500	+33%	+$368K	0.86%	43
2023 Q1	$888K	Buy	82,500 +37,500	+83%	+$494K	0.61%	59
2022 Q4	$674K	Buy	45,000 +2,000	+5%	+$29.1K	0.67%	55
2022 Q3	$552K	Buy	+43,000	New	+$490K	0.57%	53
2021 Q3	–	Sell	-32,500	Closed	-$453K	–	211
2021 Q2	$453K	Buy	32,500 +13,500	+71%	+$205K	0.12%	68
2021 Q1	$352K	Buy	19,000 +3,500	+23%	+$71.6K	0.12%	66
2020 Q4	$274K	Buy	15,500 +11,500	+288%	+$202K	0.11%	46
2020 Q3	$61K	Buy	+4,000	New	+$75.1K	0.03%	93

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

AlphaCentric Advisors's KNSA Position: Q3 2026 in Review

AlphaCentric Advisors opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2026: 7,987 shares worth $596K. The stake represents 0.53% of the portfolio and ranks #58 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in KNSA as recently as Q3 2024.

AlphaCentric Advisors first reported a position in KNSA in Q3 2020 and has held it in 11 quarters since. The position peaked at $1.91M in Q3 2023. 226 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

AlphaCentric Advisors held 7,987 shares of Kiniksa Pharmaceuticals worth $596K as of Q3 2026.
Kiniksa Pharmaceuticals was a new AlphaCentric Advisors position in Q3 2026.
Kiniksa Pharmaceuticals made up 0.53% of AlphaCentric Advisors's portfolio in Q3 2026, its #58 holding.
AlphaCentric Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
AlphaCentric Advisors's Kiniksa Pharmaceuticals position peaked at $1.91M in Q3 2023.
226 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.